Dual HER2 Blockade.
نویسندگان
چکیده
a Department of Gynecology, Martin-Luther-University, Halle/Saale, Germany; b Division of Hematology-Oncology, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon; c Peter MacCallum Cancer Centre, Melbourne, Australia; d Department of Oncology and Radiotherapy, Medical University of Gda ’ nsk; Gdansk, Poland; e Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA; f Gynecology Clinic, HELIOS Hospital Berlin Buch, Berlin, Germany
منابع مشابه
Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials
Although dual HER-2 blockade treatment could offer greater clinical efficacy in breast cancer, the risk of severe toxicities of special interest related to this combined regimen in breast cancer remained unknown. We systematically searched public databases (MEDLINE, EMBASE, Cochrane library) to identify relevant studies that comparing anti-HER2 monotherapy (lapatinib or trastuzumab or pertuzuma...
متن کاملCancer Therapy: Preclinical Dual Blockade of HER2 inHER2-Overexpressing TumorCells Does Not Completely Eliminate HER3 Function
Purpose: Dual blockade of HER2 with trastuzumab and lapatinib or with pertuzumab is a superior treatment approach compared with single-agent HER2 inhibitors. However, many HER2-overexpressing breast cancers still escape from this combinatorial approach. Inhibition of HER2 and downstream phosphoinositide 3-kinase (PI3K)/AKT causes a transcriptional and posttranslational upregulation of HER3 whic...
متن کاملDual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.
PURPOSE Dual blockade of HER2 with trastuzumab and lapatinib or with pertuzumab is a superior treatment approach compared with single-agent HER2 inhibitors. However, many HER2-overexpressing breast cancers still escape from this combinatorial approach. Inhibition of HER2 and downstream phosphoinositide 3-kinase (PI3K)/AKT causes a transcriptional and posttranslational upregulation of HER3 which...
متن کاملDual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase transmembrane receptor that is overexpressed on the surface of 15%-20% of breast tumors and has been associated with poor prognosis. Consistently improved pathologic response and survival rates have been demonstrated with use of trastuzumab in combination with standard chemotherapy in both early and advanced breast cancer. How...
متن کاملBeyond trastuzumab and lapatinib: new options for HER2-positive breast cancer .
HER2-positive breast cancer (BC) constitutes a molecular subtype of the disease with an aggressive biologic behavior. Trastuzumab revolutionized the treatment of this disease, changing its natural history. Lapatinib is active in the metastatic setting, approved for patients who were pretreated with trastuzumab. However, resistance to anti-HER2 agents is a major clinical issue, occurring in both...
متن کاملIntrinsic molecular subtypes of HER2+ breast cancer
HER2-positive (HER2+) breast cancer is a clinically and biologically heterogeneous disease. According to gene expression profiling, 4 main intrinsic molecular subtypes of breast cancer (Luminal A, Luminal B, HER2-enriched [HER2-E], Basal-like) can be identified, although HER2-E predominates (~50-60%). From a molecular perspective, HER2-E tumors are characterized by high expression of ERBB2 and ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Breast care
دوره 12 5 شماره
صفحات -
تاریخ انتشار 2017